Valuation: Prothena Corporation plc

Market Cap 484M 423M 390M 360M 684M 46.14B 695M 4.66B 1.83B 22.73B 1.82B 1.78B 78.14B P/E 2026 *
198x
P/E 2027 * -8.97x
Enterprise Value 484M 423M 390M 360M 684M 46.14B 695M 4.66B 1.83B 22.73B 1.82B 1.78B 78.14B EV / Sales 2026 *
5.81x
EV / Sales 2027 * 22x
Free-Float
79.82%
Yield 2026 *
-
Yield 2027 * -
1 day-4.15%
1 week-4.64%
Current month-5.62%
1 month+11.86%
3 months-12.00%
6 months+0.54%
Current year-3.25%
1 week 9.03
Extreme 9.03
10.02
1 month 7.85
Extreme 7.85
10.15
Current year 7.73
Extreme 7.73
11.8
1 year 6.16
Extreme 6.16
11.8
3 years 4.32
Extreme 4.32
73.14
5 years 4.32
Extreme 4.32
79.75
10 years 4.32
Extreme 4.32
79.75
Manager TitleAgeSince
Chief Executive Officer 57 2016-09-29
Director of Finance/CFO 52 2013-03-31
Chief Tech/Sci/R&D Officer 53 2014-12-31
Director TitleAgeSince
Chairman 76 2012-12-19
Director/Board Member 72 2012-12-19
Director/Board Member 63 2012-12-19
Date Insider Type Main position Quantity % Market Cap.
06-15Buy 20,000 0.0382%
06-14Don -325,000 0.6208%
06-10Buy 125,000 0.2388%
Change 5-day change 1-year change 3-year change Capi.($)
-4.15%-4.64%+44.38%-86.29% 484M
+1.84%-0.66%+59.82%+92.96% 54.88B
-4.14%-8.06%+58.96%+118.67% 54.63B
-2.24%+3.59%+17.75%+477.47% 25.06B
-1.60%-6.21%-18.96%-15.21% 23.14B
+2.43%+1.06%+42.44%-1.27% 19.88B
-3.19%0.00%+35.60%-26.98% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
+8.74%+3.51%+51.91%+726.40% 15.36B
-1.05%+1.16%+25.95%+194.27% 14.2B
Average -1.02%-0.71%+51.30%+183.72% 24.17B
Weighted average by Cap. -0.92%-1.46%+51.25%+175.73%

Financials

2026 *2027 *
Net sales 83.32M 72.88M 67.22M 62.09M 118M 7.95B 120M 803M 315M 3.91B 313M 306M 13.46B 22M 19.24M 17.75M 16.39M 31.11M 2.1B 31.63M 212M 83.28M 1.03B 82.6M 80.81M 3.55B
Net income 2.42M 2.12M 1.96M 1.81M 3.43M 231M 3.48M 23.36M 9.17M 114M 9.1M 8.9M 391M -55.93M -48.92M -45.12M -41.67M -79.08M -5.33B -80.41M -539M -212M -2.63B -210M -205M -9.03B
Net Debt - -
Logo Prothena Corporation plc
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Employees
67
Date Price Change Volume
26-07-10 US$9.240 -4.15% 505,130
26-07-09 US$9.640 -2.13% 482,229
26-07-08 US$9.850 +1.76% 444,245
26-07-07 US$9.680 +1.89% 520,542
26-07-06 US$9.500 -1.96% 403,737
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
9.240USD
Average target price
21.40USD
Spread / Average Target
+131.60%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRTA Stock